Vetnostrum (6936) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 永鴻生技

Vetnostrum (6936) reported revenue of NT$134.8 million for Oct 2026, +13.8% year on year and +15.8% from the previous month. Revenue for Jan–Oct 2026 was NT$1.25 billion (+8.0% year on year).

In Oct 2026, it ranked No. 60 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$105.7 million24/10Nov 2024 NT$95 millionDec 2024 NT$124.8 millionJan 2025 NT$121.8 millionFeb 2025 NT$104.6 million25/02Mar 2025 NT$114.3 millionApr 2025 NT$104 millionMay 2025 NT$105.8 millionJun 2025 NT$117.8 million25/06Jul 2025 NT$128.7 millionAug 2025 NT$121.4 millionSep 2025 NT$125.1 millionOct 2025 NT$118.4 million25/10Nov 2025 NT$134.1 millionDec 2025 NT$120.1 millionJan 2026 NT$143.8 millionFeb 2026 NT$92.3 million26/02Mar 2026 NT$132.3 millionApr 2026 NT$132.3 millionMay 2026 NT$126.1 millionJun 2026 NT$117.3 million26/06Jul 2026 NT$145.6 millionAug 2026 NT$113.8 millionSep 2026 NT$116.4 millionOct 2026 NT$134.8 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$134.8 million+13.8%+15.8%
Sep 2026NT$116.4 million-6.9%+2.3%
Aug 2026NT$113.8 million-6.2%-21.8%
Jul 2026NT$145.6 million+13.1%+24.1%
Jun 2026NT$117.3 million-0.4%-7.0%
May 2026NT$126.1 million+19.3%-4.6%
Apr 2026NT$132.3 million+27.2%+0.0%
Mar 2026NT$132.3 million+15.7%+43.3%
Feb 2026NT$92.3 million-11.7%-35.8%
Jan 2026NT$143.8 million+18.1%+19.7%
Dec 2025NT$120.1 million-3.8%-10.4%
Nov 2025NT$134.1 million+41.2%+13.3%
Oct 2025NT$118.4 million+12.0%-5.3%
Sep 2025NT$125.1 million+16.6%+3.1%
Aug 2025NT$121.4 million-9.6%-5.7%
Jul 2025NT$128.7 million+7.9%+9.3%
Jun 2025NT$117.8 million+9.2%+11.4%
May 2025NT$105.8 million-6.5%+1.7%
Apr 2025NT$104 million-2.7%-9.1%
Mar 2025NT$114.3 million+32.7%+9.3%
Feb 2025NT$104.6 million+26.0%-14.1%
Jan 2025NT$121.8 million+9.9%-2.4%
Dec 2024NT$124.8 million+19.5%+31.4%
Nov 2024NT$95 million-2.3%-10.1%
Oct 2024NT$105.7 million+16.3%-1.5%

Jan–Oct 2026 cumulative: NT$1.25 billion (+8.0% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Vetnostrum vs PEC / Vetnostrum vs Lotus Pharm / Vetnostrum vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16